These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 3673100)

  • 1. [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
    Lechleitner P; Gmeiner R; Beck G; König P
    Wien Med Wochenschr; 1987 Aug; 137(14-15):355-60. PubMed ID: 3673100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aluminum and renal osteodystrophy.
    Nebeker HG; Coburn JW
    Annu Rev Med; 1986; 37():79-95. PubMed ID: 3085581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Successful treatment of progressive dialysis encephalopathy. Case report].
    Weiland P; Köhler M; Glatzel E
    Z Urol Nephrol; 1985 Jul; 78(7):387-93. PubMed ID: 4050157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of various treatment modalities on aluminium associated bone disease.
    Ihle BU; Buchanan MR; Stevens B; Becker GJ; Kincaid-Smith P
    Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aluminum osteopathy--experience with therapy].
    Sulková S
    Vnitr Lek; 1993 May; 39(5):459-63. PubMed ID: 8351877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical images: Aluminum-modified renal osteopathy.
    Buttgereit F; Loreck D; Burmester GR; Abendroth K
    Arthritis Rheum; 1997 Sep; 40(9):1724. PubMed ID: 9324031
    [No Abstract]   [Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine.
    Warady BA; Ford DM; Gaston CE; Sedman AB; Huffer WE; Lum GM
    Pediatrics; 1986 Oct; 78(4):651-5. PubMed ID: 3763276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P; Ralston AJ; Day JP
    Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
    [No Abstract]   [Full Text] [Related]  

  • 12. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 14. [The role of aluminum in the human body].
    Strzałkowska D
    Postepy Hig Med Dosw; 1991; 45(3-4):257-79. PubMed ID: 1946095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Unusual course of renal osteopathy with Paget's disease and aluminum deposits].
    Ringe JD; Delling G
    Dtsch Med Wochenschr; 1985 Mar; 110(11):411-5. PubMed ID: 3979272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of aluminum-associated bone disease in long-term hemodialysis patients.
    Iwamoto N; Ono T; Yamazaki S; Fukuda T; Kondo M; Yamamoto N; Hiratake Y; Masugi Y; Kubo Y; Hino M
    Nephron; 1986; 42(3):204-9. PubMed ID: 3945360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
    Graf H; Stummvoll HK; Meisinger V
    Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy.
    Milne FJ; Sharf B; Bell P; Meyers AM
    Clin Nephrol; 1983 Oct; 20(4):202-7. PubMed ID: 6641027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aluminum toxicity in children with chronic renal failure.
    Polinsky MS; Gruskin AB
    J Pediatr; 1984 Nov; 105(5):758-61. PubMed ID: 6389807
    [No Abstract]   [Full Text] [Related]  

  • 20. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.